Metformin er 500mg 24hr tabs
Pro Research Analysisby 
Searched over 200M research papers
Metformin ER 500mg 24hr Tablets: Efficacy, Tolerability, and Patient Adherence
Introduction to Metformin ER 500mg Tablets
Metformin extended-release (ER) 500mg tablets are a novel formulation designed to improve glycemic control in patients with type 2 diabetes mellitus (T2DM). This formulation allows for once-daily dosing, which can enhance patient adherence and satisfaction compared to immediate-release (IR) formulations.
Pharmacokinetics and Bioavailability
The pharmacokinetics of metformin ER 500mg tablets show that the drug is retained in the stomach for approximately 8 hours, allowing for gradual absorption in the upper gastrointestinal tract. This results in a delayed time to maximum plasma concentration (Tmax) of 7.5 hours compared to 4.2 hours for metformin IR. Studies have demonstrated that the systemic exposure (AUC) of metformin ER is comparable to that of metformin IR when administered at equivalent doses .
Glycemic Control and Efficacy
Clinical trials have shown that metformin ER provides effective glycemic control similar to metformin IR. In a 24-week randomized trial, patients receiving metformin ER 1500-2000 mg/day achieved comparable reductions in HbA1c levels to those receiving metformin IR 1500 mg/day. Additionally, a higher percentage of patients on metformin ER 2000 mg/day achieved the American Diabetes Association-recommended HbA1c level of <7% compared to those on metformin IR 1500 mg/day.
Tolerability and Side Effects
Metformin ER is generally well tolerated, with a side effect profile similar to that of metformin IR. Notably, the incidence of nausea is significantly lower with metformin ER, particularly in the first week of treatment, suggesting that more rapid dose titration may be feasible. This improved tolerability can enhance patient adherence and overall satisfaction with the treatment.
Patient Adherence and Satisfaction
A postmarketing observational study in India compared patient adherence and satisfaction between metformin ER and a smaller-sized metformin prolonged-release (PR) tablet. The study found that patients preferred the PR formulation due to its smaller size, ease of swallowing, and lack of aftertaste. However, the ghost pill effect was less common with the PR formulation compared to the ER formulation. Despite these differences, both formulations were effective in improving patient adherence and satisfaction.
Comparative Studies and Combination Therapies
Comparative studies have shown that metformin ER, when combined with other antidiabetic agents like glyburide, provides superior glycemic control compared to glyburide plus placebo. Additionally, a study comparing a fixed-dose combination of ertugliflozin and metformin IR with the individual components found that the combination was bioequivalent and well-tolerated, supporting its use in clinical practice.
Conclusion
Metformin ER 500mg tablets offer a viable alternative to metformin IR for patients with T2DM, providing effective glycemic control with improved tolerability and patient adherence. The once-daily dosing regimen and reduced incidence of gastrointestinal side effects make metformin ER a preferred option for many patients. Further studies and real-world data continue to support its efficacy and safety profile, making it a cornerstone in the management of T2DM.
Sources and full results
Most relevant research papers on this topic